Eculizumab in gemcitabine-induced thrombotic microangiopathy: experience of the French thrombotic microangiopathies reference centre

Eculizumab in gemcitabine-induced thrombotic microangiopathy: experience of the French thrombotic microangiopathies reference centre

Abstract Background Gemcitabine is a broadly prescribed chemotherapy, the use of which can be limited by renal adverse events, including thrombotic microangiopathy (TMA). Methods This study evaluated the efficacy of eculizumab, a monoclonal antibody targeting the terminal complement pathway, in pati...

Full description

Bibliographic Details
Main Authors: Maximilien Grall, Florence Daviet, Noémie Jourde Chiche, François Provot, Claire Presne, Jean-Philippe Coindre, Claire Pouteil-Noble, Alexandre Karras, Dominique Guerrot, Arnaud François, Ygal Benhamou, Agnès Veyradier, Véronique Frémeaux-Bacchi, Paul Coppo, Steven Grangé
Format: Article
Language:English
Published: BMC 2021-07-01
Series:BMC Nephrology
Subjects:
Coagulation, thrombotic disorders and therapies, Cancer and thrombosis
Eculizumab
Gemcitabine-induced thrombotic microangiopathy
Online Access:https://doi.org/10.1186/s12882-021-02470-3

Internet

https://doi.org/10.1186/s12882-021-02470-3

Similar Items